Brian Druker is the Chief Executive Officer of the OHSU Knight Cancer Institute, where he has led efforts to transform cancer care and research. He is renowned for having a major role in developing Gleevec, the first drug to specifically target cancer cells, which turned chronic myeloid leukemia (CML) from a fatal disease into a manageable condition and launched the era of precision cancer medicine. Since becoming director of the Knight Cancer Institute in 2007, Dr. Druker has overseen major initiatives including the Cancer Early Detection Advanced Research Center (CEDAR) and the BEAT AML national clinical trial, advancing innovative treatments for leukemia and other cancers.
Dr. Druker’s work has been amplified through transformative partnerships with Phil and Penny Knight, whose gifts – including a record $2 billion donation – have supported a fully integrated cancer care model providing clinical trials and comprehensive patient support. Born in 1955 in St. Paul, Minnesota, Dr. Druker earned his chemistry degree and medical degree at the University of California, San Diego, and pursued early research at Dana-Farber Cancer Institute before joining OHSU. He continues to lead research and clinical programs that bridge laboratory discovery and patient care, positioning the Knight Cancer Institute as a national leader in precision oncology.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations.
